Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners dropped their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Down 1.1 %

AWH opened at $0.93 on Friday. The firm has a market cap of $14.94 million, a P/E ratio of -0.64 and a beta of 1.47. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65. The business’s fifty day simple moving average is $0.90 and its 200 day simple moving average is $1.62.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter last year, the business earned ($0.28) earnings per share. As a group, equities analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. raised its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.